Declining System Sales Drag Cepheid Q1 Revenues Down 13 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid reported on Thursday afternoon that its first-quarter revenue fell 13 percent year over year, largely due to a 45 percent drop in system sales.

The firm brought in revenues of $38.8 million for the three-month period ended March 31, compared to revenues of $44.8 million in the first quarter of 2008.

System sales dropped to $7.9 million from $14.3 million year over year, while sales of reagents and disposables increased 4 percent to $28.7 million from $27.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.